Roche presents positive late-stage Hemlibra data
Haemophilia A is an inherited, serious disorder in which a person’s blood does not clot properly.
Read Moreby Anna Smith | Jul 9, 2019 | News | 0
Haemophilia A is an inherited, serious disorder in which a person’s blood does not clot properly.
Read Moreby Selina McKee | May 22, 2018 | News | 0
Data from two late-stage studies further support use of Roche’s Hemlibra in a much broader population of haemophilia patients.
Read Moreby Selina McKee | Nov 20, 2017 | News | 0
Roche’s Hemlibra has hit key targets in a Phase III trial assessing its effectiveness in preventing bleeds in adults and adolescents with haemophilia A without inhibitors to factor VIII.
Read Moreby Selina McKee | Jun 26, 2017 | News | 0
Roche has presented a new batch of data showing that its experimental bispecific monoclonal antibody emicizumab significantly reduced bleeds in patients with haemophilia A and inhibitors to factor VIII.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
